Glands were collected at 10 weeks post-transplantation for DCIS.COM, and at 14 weeks for SUM225, and prepared for IF using antibodies for BCL9 to confirm in vivo KD, human cytokeratin 5 and 19 (K5 and K19) to detect in vivo growth of human DCIS-like lesions, SMA to detect the myoepithelial layer, phospho-histone 3 (phosphoH3) to detect cell proliferation, and cleaved caspase 3 to detect apoptosis. The gene discussed is BCL9; the disease is ductal breast carcinoma in situ.